Trial Profile

A Multiple-Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3209590 in Japanese Patients With Type 2 Diabetes Mellitus

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin efsitora alfa (Primary) ; Insulin degludec
Indications Type 2 diabetes mellitus
Focus Adverse reactions
Sponsors Eli Lilly and Company

Most Recent Events

07 Jun 2022 Results assessing safety, pharmacokinetics, and pharmacodynamics of once-weekly Basal Insulin Fc (BIF) in Japanese patients with Type 2 Diabetes presented at the 82nd Annual Scientific Sessions of the American Diabetes Association.
02 Dec 2020 Status changed from active, no longer recruiting to completed.
17 Sep 2020 Planned End Date changed from 14 Dec 2020 to 28 Nov 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com